What happened

C.R. Bard (NYSE:BCR) stock soared 19.5% higher on Monday after medical supply giant Becton, Dickinson (NYSE:BDX) announced it's acquiring the company for about $24 billion in cash and stock.

So what

Becton, Dickinson will pay C.R. Bard investors $222.93 per share in cash plus 0.5077 shares of BD for each share they own of C.R. Bard. 

A rocket soars into outer space.

Image source: Getty Images.

It's an attractive deal for BD because it gives it exposure to vascular, urology, oncology, and specialty surgery markets that are growing due to a larger, longer-living, and wealthier global population. 

The acquisition should accelerate BD's top- and bottom-line growth because C.R. Bard is growing more quickly (organically) than BD.

In 2016, C.R. Bard's sales increased 9% to $3.7 billion and its adjusted net income increased 12% to $777.3 million. In January, management told investors to expect sales to grow between 4% and 5% this year, and for adjusted EPS to grow to between $11.45 and $11.75, up from $10.29 in 2016.

For perspective, BD's pre-deal guidance for this fiscal year was for revenue to decrease 3.5% to 4% and for adjusted EPS of $9.35 to $9.45, up 9% to 10% versus fiscal 2016.

Now what

Once the deal is done, Becton, Dickinson thinks it can deliver revenue and cost synergies of $300 million annually in 2020. C.R. Bard's higher margins have management estimating that the deal will add 3% to gross margin, as well as boost its annual EPS growth into the teens.

C.R. Bard investors will have to decide if those estimates are good enough to convince them to stick around and own BD's shares, especially since BD is taking on $10 billion in debt to finance this deal.

Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool recommends Becton Dickinson. The Motley Fool has a disclosure policy.